Katie Insogna serves as Co-Chair of the Pharmaceutical and Medical Device Product Liability Sub-Practice Group. A six-time honoree by Legal 500 for life sciences and pharmaceutical and medical device defense (2020 as a Rising Star; 2021 – 2025 as a Next Generation Partner), Katie’s practice focuses on litigation, regulatory, and enforcement challenges facing pharmaceutical, medical device, and life science companies. Her litigation practice primarily involves representing clients in complex, multi-jurisdictional product liability litigation and complex commercial litigation, for which DLA Piper’s Product Liability and Mass Tort practice group has been recognized as a leader for years. As part of her Legal 500 recognition, Katie was described as “highly skilled” and “a name to note.” Clients recognized that she “excels at handling high-stakes litigation and counselling” and “recommended for her ability to handle both regulatory issues and litigation, including MDLs tied to product liability, and broader commercial litigation.”
Katie has extensive expertise with fact and expert witness development, discovery and dispositive motion practice, and trial preparation. Katie has taken and defended numerous expert, party, and third-party witness depositions in product liability and commercial litigation cases. She has Science Day and Daubert hearing experience, and has argued motions in state and federal courts.
In addition to her litigation practice, Katie counsels clients on research and development, risk management, and other compliance issues.
